View in EDS PDF Full Text

Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis.

Saved in:
Bibliographic Details
Title: Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis.
Alternate Title: Rentabilidad médica de la vacunación antineumocócica en América Latina y el Caribe: un análisis regional.
Authors: Anushua Sinha1,2 sinhaan1@umdnj.edu, Constenla, Dagna3, Valencia, Juan Esteban4, O'Loughlin, Rosalyn5, Gomez, Elizabeth6, de la Hoz, Fernando7, Valenzuela, Maria Teresa8, de Quadros, Ciro A.9
Source: Pan American Journal of Public Health / Revista Panamericana de Salud Pública. Nov2008, Vol. 24 Issue 5, p304-313. 10p.
Subjects: MEDICAL care costs, COST effectiveness, PNEUMOCOCCAL vaccines, STREPTOCOCCUS pneumoniae, CHILDREN'S health
Geographic Terms: LATIN America
Abstract (English): Objective. In Latin America and the Caribbean, routine vaccination of infants against Streptococcus pneumoniae would need substantial investment by governments and donor organizations. Policymakers need information about the projected health benefits, costs, and cost-effectiveness of vaccination when considering these investments. Our aim was to incorporate vaccine, demographic, epidemiologic, and cost data into an economic analysis of pneumococcal vaccination of infants in Latin America and the Caribbean. Methods. We previously used a structured literature review to develop regional estimates of the incidence of disease. Cost data were collected from physician interviews and public fee schedules. We then constructed a decision analytic model to compare pneumococcal conjugate vaccination of infants with no vaccination across this region, examining only vaccine's direct effects on children. Results. Pneumococcal vaccination at the rate of diphtheria-tetanus-pertussis vaccine coverage was projected to prevent 9 500 deaths per year in children aged 0 to 5 years in the region, or approximately one life saved per 1 100 infants vaccinated. These saved lives as well as averted cases of deafness, motor deficit, and seizure result in 321 000 disability-adjusted life years (DALYs) being averted annually. At vaccine prices between US$5 and US$53 per dose, the cost per DALY averted from a societal perspective would range from US$154 to US$5 252. Conclusion. Pneumococcal conjugate vaccine was highly cost-effective up to $40 per dose. Introduction of pneumococcal vaccine in the Latin American and Caribbean region is projected to reduce childhood mortality and to be highly cost-effective across a range of possible costs. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): Objetivo. En América Latina y el Caribe, la vacunación sistemática de niños contra Streptococcus pneumoniae podría requerir inversiones considerables de los gobiernos y organizaciones donantes. Al evaluar estas inversiones se requiere información sobre los posibles beneficios sanitarios, costos y rentabilidad (relación costo-efectividad) de la vacunación. Se presenta un análisis económico de la vacunación infantil antineumocócica en América Latina y el Caribe a partir de la información de la vacuna y de datos demográficos, epidemiológicos y de costos. Métodos. Se realizó una revisión bibliográfica estructurada previa para llegar a estimados regionales de la incidencia de la enfermedad. Los costos se tomaron de entrevistas a médicos y tarifas públicas. Se construyó un modelo analítico de decisión para comparar la vacunación de los niños de esta región con la vacuna antineumocócica conjugada y la no vacunación, tomando en cuenta solamente el efecto directo de la vacuna en los niños. Resultados. Se proyectó la vacunación antineumocócica con las tasas de cobertura de la vacuna contra la difteria, el tétanos y la tosferina para prevenir 9 500 muertes anuales en menores de 5 años en esta región, o aproximadamente 1 vida salvada por cada 1 100 niños vacunados. Las vidas salvadas y los casos prevenidos de sordera, trastornos psicomotores y convulsiones equivalen a evitar anualmente 321 000 años de vida ajustados por incapacidad (AVAD). A un precio de la vacuna de US$ 5,00 a US$ 53,00 por dosis, el costo por AVAD evitado desde el punto de vista de la sociedad sería de US$ 154,00 a US$ 5 252,00. Conclusiones. La vacuna antineumocócica conjugada fue altamente rentable hasta un precio de US$ 40,00 por dosis. La introducción de esta vacuna en América Latina y el Caribe puede reducir la mortalidad infantil con una alta rentabilidad en un amplio espectro de posibles costos. [ABSTRACT FROM AUTHOR]
Copyright of Pan American Journal of Public Health / Revista Panamericana de Salud Pública is the property of Pan American Health Organization and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: lth
DbLabel: MedicLatina
An: 37246243
AccessLevel: 6
PubType: Periodical
PubTypeId: serialPeriodical
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis.
– Name: TitleAlt
  Label: Alternate Title
  Group: TiAlt
  Data: Rentabilidad médica de la vacunación antineumocócica en América Latina y el Caribe: un análisis regional.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Anushua+Sinha%22">Anushua Sinha</searchLink><relatesTo>1,2</relatesTo><i> sinhaan1@umdnj.edu</i><br /><searchLink fieldCode="AR" term="%22Constenla%2C+Dagna%22">Constenla, Dagna</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Valencia%2C+Juan+Esteban%22">Valencia, Juan Esteban</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22O'Loughlin%2C+Rosalyn%22">O'Loughlin, Rosalyn</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Gomez%2C+Elizabeth%22">Gomez, Elizabeth</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22de+la+Hoz%2C+Fernando%22">de la Hoz, Fernando</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22Valenzuela%2C+Maria+Teresa%22">Valenzuela, Maria Teresa</searchLink><relatesTo>8</relatesTo><br /><searchLink fieldCode="AR" term="%22de+Quadros%2C+Ciro+A%2E%22">de Quadros, Ciro A.</searchLink><relatesTo>9</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Pan+American+Journal+of+Public+Health+%2F+Revista+Panamericana+de+Salud+Pública%22">Pan American Journal of Public Health / Revista Panamericana de Salud Pública</searchLink>. Nov2008, Vol. 24 Issue 5, p304-313. 10p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22MEDICAL+care+costs%22">MEDICAL care costs</searchLink><br /><searchLink fieldCode="DE" term="%22COST+effectiveness%22">COST effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22PNEUMOCOCCAL+vaccines%22">PNEUMOCOCCAL vaccines</searchLink><br /><searchLink fieldCode="DE" term="%22STREPTOCOCCUS+pneumoniae%22">STREPTOCOCCUS pneumoniae</searchLink><br /><searchLink fieldCode="DE" term="%22CHILDREN'S+health%22">CHILDREN'S health</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22LATIN+America%22">LATIN America</searchLink>
– Name: Abstract
  Label: Abstract (English)
  Group: Ab
  Data: Objective. In Latin America and the Caribbean, routine vaccination of infants against Streptococcus pneumoniae would need substantial investment by governments and donor organizations. Policymakers need information about the projected health benefits, costs, and cost-effectiveness of vaccination when considering these investments. Our aim was to incorporate vaccine, demographic, epidemiologic, and cost data into an economic analysis of pneumococcal vaccination of infants in Latin America and the Caribbean. Methods. We previously used a structured literature review to develop regional estimates of the incidence of disease. Cost data were collected from physician interviews and public fee schedules. We then constructed a decision analytic model to compare pneumococcal conjugate vaccination of infants with no vaccination across this region, examining only vaccine's direct effects on children. Results. Pneumococcal vaccination at the rate of diphtheria-tetanus-pertussis vaccine coverage was projected to prevent 9 500 deaths per year in children aged 0 to 5 years in the region, or approximately one life saved per 1 100 infants vaccinated. These saved lives as well as averted cases of deafness, motor deficit, and seizure result in 321 000 disability-adjusted life years (DALYs) being averted annually. At vaccine prices between US$5 and US$53 per dose, the cost per DALY averted from a societal perspective would range from US$154 to US$5 252. Conclusion. Pneumococcal conjugate vaccine was highly cost-effective up to $40 per dose. Introduction of pneumococcal vaccine in the Latin American and Caribbean region is projected to reduce childhood mortality and to be highly cost-effective across a range of possible costs. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label: Abstract (Spanish)
  Group: Ab
  Data: Objetivo. En América Latina y el Caribe, la vacunación sistemática de niños contra Streptococcus pneumoniae podría requerir inversiones considerables de los gobiernos y organizaciones donantes. Al evaluar estas inversiones se requiere información sobre los posibles beneficios sanitarios, costos y rentabilidad (relación costo-efectividad) de la vacunación. Se presenta un análisis económico de la vacunación infantil antineumocócica en América Latina y el Caribe a partir de la información de la vacuna y de datos demográficos, epidemiológicos y de costos. Métodos. Se realizó una revisión bibliográfica estructurada previa para llegar a estimados regionales de la incidencia de la enfermedad. Los costos se tomaron de entrevistas a médicos y tarifas públicas. Se construyó un modelo analítico de decisión para comparar la vacunación de los niños de esta región con la vacuna antineumocócica conjugada y la no vacunación, tomando en cuenta solamente el efecto directo de la vacuna en los niños. Resultados. Se proyectó la vacunación antineumocócica con las tasas de cobertura de la vacuna contra la difteria, el tétanos y la tosferina para prevenir 9 500 muertes anuales en menores de 5 años en esta región, o aproximadamente 1 vida salvada por cada 1 100 niños vacunados. Las vidas salvadas y los casos prevenidos de sordera, trastornos psicomotores y convulsiones equivalen a evitar anualmente 321 000 años de vida ajustados por incapacidad (AVAD). A un precio de la vacuna de US$ 5,00 a US$ 53,00 por dosis, el costo por AVAD evitado desde el punto de vista de la sociedad sería de US$ 154,00 a US$ 5 252,00. Conclusiones. La vacuna antineumocócica conjugada fue altamente rentable hasta un precio de US$ 40,00 por dosis. La introducción de esta vacuna en América Latina y el Caribe puede reducir la mortalidad infantil con una alta rentabilidad en un amplio espectro de posibles costos. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Pan American Journal of Public Health / Revista Panamericana de Salud Pública is the property of Pan American Health Organization and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=37246243
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1590/S1020-49892008001100002
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 304
    Subjects:
      – SubjectFull: MEDICAL care costs
        Type: general
      – SubjectFull: COST effectiveness
        Type: general
      – SubjectFull: PNEUMOCOCCAL vaccines
        Type: general
      – SubjectFull: STREPTOCOCCUS pneumoniae
        Type: general
      – SubjectFull: CHILDREN'S health
        Type: general
      – SubjectFull: LATIN America
        Type: general
    Titles:
      – TitleFull: Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Anushua Sinha
      – PersonEntity:
          Name:
            NameFull: Constenla, Dagna
      – PersonEntity:
          Name:
            NameFull: Valencia, Juan Esteban
      – PersonEntity:
          Name:
            NameFull: O'Loughlin, Rosalyn
      – PersonEntity:
          Name:
            NameFull: Gomez, Elizabeth
      – PersonEntity:
          Name:
            NameFull: de la Hoz, Fernando
      – PersonEntity:
          Name:
            NameFull: Valenzuela, Maria Teresa
      – PersonEntity:
          Name:
            NameFull: de Quadros, Ciro A.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: Nov2008
              Type: published
              Y: 2008
          Identifiers:
            – Type: issn-print
              Value: 10204989
          Numbering:
            – Type: volume
              Value: 24
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Pan American Journal of Public Health / Revista Panamericana de Salud Pública
              Type: main
ResultId 1